Compare AbbVie Inc (ABBV) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Target Corporation — how do they compare? AbbVie Inc trades at $248.85 (market cap $441.94B), while Target Corporation trades at $152.46 (market cap $69.17B). The key difference: AbbVie Inc is far larger — about 6.4× Target Corporation's market cap, and Target Corporation pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| ABBV | TGT | |
|---|---|---|
Market Cap | $441.94B | $69.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $152.35 |
52-Week Low | $197.38 | $83.68 |
Enterprise Value | $506.19B | $84.47B |
Dividend Yield | 2.77% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Target (TGT) trades at $152.09, up 1.6% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Valuation metrics show a P/E of 20.12 and P/S of 0.65, while profitability remains solid with a 22.02% ROE. Recent news highlights the appointment of a Chief AI Officer, signaling strategic focus on technology.
The outlook for TGT is positive, driven by earnings momentum and AI initiatives, but risks include competitive retail pressures and potential margin compression. Analyst consensus is mixed with a $147.72 price target, suggesting limited upside from current levels, though institutional buying activity supports bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
